WaveMan
WaveMan · Company
OPK · Opko Health, Inc.
> Search tickers & screens ⌘K
LIVE
← All companies

OPK Opko Health (OPK) Insider Trading, Ownership & Congress Trades

Pharma & Biotech · Pharmaceutical preparations · CIK 0000944809
Quote by TradingView
SEC filings
Insider buyers, 180 days
0
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
98
13F, latest reported quarter

Opko Health insider trades (Form 4)

Form 4 buys and sells (codes P and S). Grants, option exercises and conversions excluded.

No insider purchases or sales are on record for OPKO HEALTH, INC. in the period covered. Source: SEC Form 4 filings, as of 2026-10-28.

Insider
Filed
Shares
Value
Since filing
PAGANELLI JOHN A
Director
BUY
2026-03-20 SEC
10,000
$11.4K
+41.7%
Context
  • 1 earlier Form 4 trade (code P or S) here by this insider (1 buy), the last on Jan 5, 2024.
  • The trade is 2.5% of the 394,340 shares held after it.
  • No other insider bought within 30 days.
  • 98 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director PAGANELLI JOHN A bought about $11.4K of OPK on Mar 20, 2026; 98 funds added in the latest 13F quarter.
Frost Gamma Investments Trust
CEO & Chairman
BUY
2025-11-21 SEC
89,375
$118.9K
+25.4%
Context
  • 183 earlier Form 4 trades (code P or S) here by this insider (183 buys), the last on Nov 20, 2025.
  • +5.8% median (+5.2% mean) 90-day return after 30 previous buys.
  • The trade is 0.0% of the 216,322,088 shares held after it.
  • 1 other insider bought within 30 days.
  • 98 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: CEO & Chairman Frost Gamma Investments Trust bought about $118.9K of OPK on Nov 21, 2025; 1 other insider bought within 30 days and 98 funds added in the latest 13F quarter.
Frost Gamma Investments Trust
CEO & Chairman
BUY
2025-11-21 SEC
191,490
$254.7K
+25.4%
Context
  • 183 earlier Form 4 trades (code P or S) here by this insider (183 buys), the last on Nov 20, 2025.
  • +5.8% median (+5.2% mean) 90-day return after 30 previous buys.
  • The trade is 0.1% of the 216,513,578 shares held after it.
  • 1 other insider bought within 30 days.
  • 98 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: CEO & Chairman Frost Gamma Investments Trust bought about $254.7K of OPK on Nov 21, 2025; 1 other insider bought within 30 days and 98 funds added in the latest 13F quarter.
Frost Gamma Investments Trust
CEO & Chairman
BUY
2025-11-21 SEC
3,894
$5.1K
+25.4%
Context
  • 183 earlier Form 4 trades (code P or S) here by this insider (183 buys), the last on Nov 20, 2025.
  • +5.8% median (+5.2% mean) 90-day return after 30 previous buys.
  • The trade is 0.0% of the 216,232,713 shares held after it.
  • 1 other insider bought within 30 days.
  • 98 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: CEO & Chairman Frost Gamma Investments Trust bought about $5.1K of OPK on Nov 21, 2025; 1 other insider bought within 30 days and 98 funds added in the latest 13F quarter.
Frost Gamma Investments Trust
CEO & Chairman
BUY
2025-11-21 SEC
102,371
$133.1K
+25.4%
Context
  • 183 earlier Form 4 trades (code P or S) here by this insider (183 buys), the last on Nov 20, 2025.
  • +5.8% median (+5.2% mean) 90-day return after 30 previous buys.
  • The trade is 0.0% of the 216,228,819 shares held after it.
  • 1 other insider bought within 30 days.
  • 98 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: CEO & Chairman Frost Gamma Investments Trust bought about $133.1K of OPK on Nov 21, 2025; 1 other insider bought within 30 days and 98 funds added in the latest 13F quarter.
480 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
See all insider buying · insider selling
Showing the latest few. to see 475 more transactions and use the screener and CSV export. We store only your email; there is no password.
Seven facts, ranked against the sector · Rank is not a forecast
Insiders
no insider buys or sells on file
Congress
no House purchase disclosed in the last 12 months
Funds
98 funds bought in last quarter
more than 67% of Pharma & Biotech
Revenue
-14.9% year over year
below 67% of Pharma & Biotech
Margin
-37.2% net margin
more than 53% of Pharma & Biotech
Buybacks
$17.8M repurchased, FY to 2026-06-30
below 63% of Pharma & Biotech
Short interest
11.0% of the float short (float per yahoo 2026-10-26) · 14.9 days to cover · settled 2026-09-30
more than 50% of Pharma & Biotech
What changed in the last 30 days
Nothing new filed in the last 30 days

Watch OPK

A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.

The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
+7.2%12M
-28%-14%+0%+14%2025-102025-122026-022026-042026-062026-082026-10 2025-11-20 · Frost Gamma Investments Trust bought $281.9K2025-11-18 · Frost Gamma Investments Trust bought $272.1K2025-11-19 · Frost Gamma Investments Trust bought $262.6K2025-11-21 · Frost Gamma Investments Trust bought $258.4K2025-11-21 · Frost Gamma Investments Trust bought $254.7K2025-11-20 · Frost Gamma Investments Trust bought $216.8K2025-10-31 · FROST PHILLIP MD ET AL bought $213.0K2025-11-19 · Frost Gamma Investments Trust bought $205.3K2025-11-20 · Frost Gamma Investments Trust bought $157.3K2025-11-21 · Frost Gamma Investments Trust bought $133.1K2025-11-21 · Frost Gamma Investments Trust bought $118.9K2025-11-18 · Frost Gamma Investments Trust bought $107.8K2025-11-18 · Frost Gamma Investments Trust bought $89.3K2025-11-19 · Frost Gamma Investments Trust bought $87.1K2025-11-18 · Frost Gamma Investments Trust bought $84.0K2025-11-19 · Frost Gamma Investments Trust bought $75.0K2025-11-20 · Frost Gamma Investments Trust bought $62.6K2025-11-18 · Frost Gamma Investments Trust bought $62.0K2025-11-19 · Frost Gamma Investments Trust bought $46.5K2025-11-18 · Frost Gamma Investments Trust bought $43.3K2025-11-19 · Frost Gamma Investments Trust bought $39.1K2025-11-20 · Frost Gamma Investments Trust bought $32.9K2025-11-19 · Frost Gamma Investments Trust bought $27.6K2025-11-18 · Frost Gamma Investments Trust bought $19.1K2025-11-20 · Frost Gamma Investments Trust bought $18.4K2025-11-19 · Frost Gamma Investments Trust bought $17.0K2026-03-20 · PAGANELLI JOHN A bought $11.4K2025-11-21 · Frost Gamma Investments Trust bought $5.1K2025-11-20 · Frost Gamma Investments Trust bought $2.4K2025-11-18 · Frost Gamma Investments Trust bought $2.3K2025-11-18 · Frost Gamma Investments Trust bought $5482025-11-18 · Frost Gamma Investments Trust bought $5122025-11-19 · Frost Gamma Investments Trust bought $3872025-11-18 · Frost Gamma Investments Trust bought $1
Insider buy
Indexed to 100, dividend-adjusted, not a price chart. When a name files heavily, the largest trades are drawn first.

Who owns OPK: institutional holders (13F)

13F holdings, latest reported quarter
Rubric Capital Management LP
47,791,243 sh
$71.7M
BlackRock, Inc.
36,978,893 sh
$55.5M
VANGUARD CAPITAL MANAGEMENT LLC
14,968,930 sh
$22.5M
VANGUARD PORTFOLIO MANAGEMENT LLC
14,934,924 sh
$22.4M
GEODE CAPITAL MANAGEMENT, LLC
11,581,027 sh
$17.4M

Congress trades in OPK

No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.

Activist and 5% holders (13D/13G)

No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.

OPK planned insider sales (Form 144)

No planned-sale notices
No insider has filed to sell. Watch this after a run-up.

OPK mutual fund holders (N-PORT)

Funds ranked by the share of their own portfolio in this stock (N-PORT).
Invesco NASDAQ Future Gen 200 ETF
$93.5K position · as of 2026-05-31
0.5%
VanEck Israel ETF
$658.0K position · as of 2026-06-30
0.4%
State Street(R) SPDR(R) S&P(R) Health Care Services ETF
$555.6K position · as of 2026-06-30
0.4%
Voya MI Dynamic Small Cap Fund
$493.5K position · as of 2026-05-31
0.3%
VOYA SMALL COMPANY PORTFOLIO
$564.5K position · as of 2026-06-30
0.3%
Goldman Sachs Small Cap Value Insights Fund
$2.7M position · as of 2026-07-31
0.2%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M · % is the share of the fund's own portfolio
Clinical pipeline
7 registered trials, 2 still running (ClinicalTrials.gov). A status change is dated here weeks before the press release.
4
Phase 2
1 active
2
Phase 3
0 active
1
Multi-phase
1 active
Matched by sponsor name. Trials run under a subsidiary's own name are not included.
Executive pay vs shareholder return
CEO pay, headline and as actually paid, against the company's return and its chosen peers' (DEF 14A).
FY
CEO total
Actually paid
Other execs, avg
TSR
Peer TSR
2025
$1.9M
$1.3M
$1.7M
-68%
+25%
2024
$2.2M
$2.0M
$2.0M
-63%
-7%
2023
$2.3M
$2.2M
$2.0M
-62%
-6%
2022
$972.2K
-$1.2M
$803.0K
-68%
-10%
2021
$2.1M
$2.4M
$2.3M
+22%
+0%
Tagged by the company under SEC Item 402(v). Returns are cumulative from the start of the disclosure period. Green where the company beat its own peer group.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
The complete filing record, in one place.
The record shows 98 funds added last quarter. Each figure is a federal filing, dated the day it went public.
Backtest this pattern Open the screener
Same sector, ranked by filing activity
Sector by SEC SIC code
UTHRCPIXMRNAREGNLLYALNYMDGLCITRDNAVRTXNUVLTWST

OPK financials

Revenue growth
-14.9%
XBRL, annual
Net margin
-37.2%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$587.9M
four quarters, 2025-07-01 to 2026-06-30
Net margin, TTM
n/a
the filed year and its quarters do not reconcile, so the trailing figure is withheld
Free cash flow, TTM
-$134.0M
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Debt to equity
0.00x
long-term 2026-06-30 plus current 2026-06-30; equity 2026-06-30
Cash flow to debt
-45.81x
TTM operating cash flow over long-term 2026-06-30 plus current 2026-06-30
Return on equity
n/a
the filed year and its quarters do not reconcile, so the trailing figure is withheld
Return on assets
n/a
the filed year and its quarters do not reconcile, so the trailing figure is withheld
Return on invested capital
n/a
pre-tax loss, no effective tax rate to apply
Return on capital employed
-2.8%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
P/E, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Enterprise value
$918.4M
market value at close 2026-10-26 on 2026-07-17 shares, plus long-term 2026-06-30 plus current 2026-06-30, minus cash 2026-06-30
FCF yield
-11.0%
TTM free cash flow over market value at close 2026-10-26
PEG, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Price as of 2026-10-26. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
2025-122024-122023-122022-12
Revenue$606.9M$713.1M$863.5M$1.0B
Gross profit$205.9M$218.5M$318.1M$288.2M
Operating income-$117.4M-$152.1M-$157.0M-$226.3M
Net income-$225.7B-$53.2B-$188.9B-$328.4B
EPS (diluted)-0.30-0.08-0.25-0.46
Operating cash flow-$178.5M-$183.5M-$28.2M-$95.2M
Cash$364.4M$426.6M$95.9M$153.2M
Long-term debt$2.3M$3.0M$7.7M$9.3M
Buybacks$47.0M$90.2M$0$0
SEC XBRL, fiscal years, as known on 2026-10-28

OPK Stock Sonar score 4/7 axes

Find similar shapesCompare

OPK ranks highest on risk and compliance (63rd percentile) and financial health (48th), and lowest on growth (33rd), among Pharma & Biotech peers.

Financial health
48
Inputs
  • Debt to equity0.00x · 83 pct, sector of 352
  • Cash flow to debt-45.81x · 12 pct, sector of 371
Growth
33
Inputs
  • Revenue growth, YoY-14.9% · 33 pct, sector of 505
  • Backlog growth, YoYno backlog line filed, or no year-earlier backlog
Institutional and government
41
Inputs
  • Funds adding, latest quarter98 · 67 pct, sector of 698
  • Congress net buyers, 365dno Congress trades in 365 days
  • Federal contracts, 180dno federal contracts in 180 days
  • Lobbying spend, 4 quarters$68K · 14 pct, sector of 133
Risk and compliance
63
Inputs
  • Short interest, % of float+11.0% · 37 pct, sector of 813
  • Recalls per $1B revenue, 3ynot measured for this sector, almost no peer has an event
  • EPA cases per $1B revenue, 5ynot measured for this sector, almost no peer has an event
  • New text in Risk Factors, latest 10-K+3.7% · 89 pct, sector of 511
3 not measured: Profitability, Insider conviction, US patents
  • Profitability needs 2 of 4 inputs, 1 present: pre-tax loss, no effective tax rate to apply; the filed year and its quarters do not reconcile, so the trailing figure is withheld
  • Insider conviction needs 1 of 2 inputs, 0 present: no Form 4 purchase or sale (code P or S) in 180 days; no insider trades in 180 days
  • US patents needs 1 of 2 inputs, 0 present: patent data not loaded yet

4 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored

Explore insider trading and ownership data

Every company we track, ranked by each kind of filing
Insider buyingInsider sellingCongress stock tradesActivist 13D stakesForm 144 planned salesCEO pay vs performanceAll companies